MUW TEAM
To be added
OUH TEAM
Else Marit Inderberg (EMI) leads a research group performing immunomonitoring in clinical immunotherapy trials and development of cellular therapy at the Translational Research Unit (Dept. for Cellular therapy, OUH). The main focus is on T-cell function and therapy as well as the identification of predictive biomarkers of therapy response. She has broad oncology-related clinical trial experience and holds an MSc equivalent degree in Immunology from France and a PhD in tumour immunology from the University of Oslo, Norway. She has co-authored several peer-reviewed publications, holds several patents, and is co-founder of two separate spin-off companies.
Else Inderberg acquired research grants from the Norwegian Research council and local funding agencies and participated in European grants and organizing international cancer vaccine conferences. More information here: https://www.linkedin.com/in/else-marit-inderberg-8177604/
Sébastien Wälchli (SW) is group leader at the Translational Research Unit (Dept. for Cellular therapy, OUH) a newly established pre-clinical entity directly connected to the immunomonitoring unit. SW leads the molecular biology of the T-cell receptor (TCR) and the Chimeric Antigen Receptor (CAR) development platforms. The TCR platform has led to the filing of numerous patents, the establishment of a biotech (Zelluna Immuntherapy AS, 2016) and the first TCR tested in human in Norway (ClinicalTrials.gov Identifier: NCT03431311). The CAR platform has completed the pre-clinical development of 2 candidates (CD37CAR: and OSCAR) and is working on around 15 new constructs, most of them directed against solid tumours. In addition, the lab is developing innovative solution for cellular therapy, such as advanced universal therapeutic solutions (NK-TCR, TCR-CAR), and different innovative tools in the immunotherapeutic field (vaccination, effector cell improvement, etc.).
More info here: www.linkedin.com/in/sebastw
Christopher Forcados (CF) is an ALTERCAR-PhD student located at OUH, who will develop alternative Chimeric Antigen Receptor (CAR) to treat B-ALL. CF holds a BSc (Biology) from the University of Strasbourg (UNISTRA, France).He then performed a MSc at the University of Reims Champagne-Ardennes (URCA, France), focused on the cellular microenvironment and its association to pathologies, especially in cancer settings. He performed one of his two internships in Pierre-Yves Dietrich’s laboratory at the University of Geneva (UNIGE, Switzerland) where he participated in the identification of T cells in tumour of GBM patients post-vaccination.
Anne Fåne (AF) is a research associate working at the Translational Research Unit (Dept. for Cellular therapy, OUH). AF is adept at designing and implementing experimental procedures in disciplines such as cellular biology, immunology and molecular biology. Her main focus is on CAR development and she is experienced in both in vitro and in vivo experimentation. Her academic credentials include a BSc in biology and an Msc in biomedical science, and she has contributed to several publications. More information here: https://www.linkedin.com/in/anne-f%C3%A5ne-2a698435/
PURE BIOLOGIC TEAM